Kota Yogyakarta

This trial is for adults who have had an acute ischemic stroke caused by a blood clot blocking a brain vessel. It focuses on people whose stroke occurred or was discovered more than 4.5 hours ago, including those who woke up with stroke symptoms. The study aims to find out if the medicine tenecteplase helps recovery when given after this 4.5-hour window, compared to standard medical care. Tenecteplase is already used within 4.5 hours after stroke onset, but this study tests its effect when given later. Participants are randomly assigned to one of two groups one receives a single injection of tenecteplase into a vein, and the other receives the usual standard treatment. Both groups have an equal chance of receiving either treatment. The study lasts about three months, starting with approximately one week of hospital stay. During the study, participants have seven clinical examinations or visits, with the final two visits conducted remotely from home to allow for easier participation. Throughout the study, doctors regularly assess participants recovery using a scale that measures disability and dependence in daily activities. They also monitor overall health and record any side effects. The main outcome measured is the level of recovery 90 days after treatment, comparing the two groups. This includes neurological improvement, bleeding events, and survival over the study period.

Researchers are evaluating the accuracy of three different transthoracic needle aspiration TTNA techniquesjabbing-then-suction, suction-with-jabbing, and suction-onlyin patients suspected of having lung cancer. The study compares these methods to assess any differences in the quality of tumor samples obtained. The research is conducted with patients who have peripheral lung tumors attached to the chest wall and who are undergoing diagnostic testing. During hospitalization, patients will receive biopsies using each of the three TTNA techniques as well as a core needle biopsy, which serves as the gold standard. The biopsy procedures are done in an operating room under local anesthesia with supervision from an anesthesiologist. These biopsy techniques are standard procedures rather than experimental methods. After the biopsy, patients are monitored for at least 24 hours to watch for any possible complications. Participants will be involved during their hospital stay where multiple biopsy techniques are performed. The quality of samples from the different TTNA methods is assessed immediately after the biopsy procedure. Careful observation follows the biopsy to ensure patient safety. The total participation includes the biopsy procedure and the 24-hour observation period for any complications related to the biopsy.

Researchers are evaluating whether home-based cardiac rehabilitation combined with a family empowerment approach can help patients recovering from acute coronary syndrome ACS. The study aims to find out if this method improves health-related quality of life and peak oxygen consumption peak Vo2 better than usual care. The trial includes adult patients aged 18 to 65 who have recently experienced ACS and have been discharged from the hospital between 3 months and 1 year prior to enrollment. Participants in the experimental group will undergo a 12-week home-based cardiac rehabilitation program that includes physical exercise, dietary management, smoking cessation, and stress management guided by educational materials and support from family and healthcare professionals. The intervention also involves regular monitoring of vital signs and exercise intensity based on a 6-minute walk test. The control group will receive usual care with education on medication adherence, exercise, smoking behavior, diet, and stress management in a single session. During the study, participants will perform prescribed walking exercises, follow diet and stress management plans, quit smoking, and comply with medication. They will visit a cardiologist at weeks 1, 6, and 12, and receive ongoing support from a nurse facilitator through video calls or home visits. Researchers will assess health-related quality of life and peak Vo2 at enrollment and after 12 weeks. Daily reports on diet, exercise, medication adherence, and heart rate during exercise will be collected and monitored to evaluate progress and safety.

Researchers are studying dovramilast, an experimental drug not yet approved for leprosy type 2 reaction erythema nodosum leprosum, ENL, to compare its effects with current standard treatments. The study focuses on adults with moderate to severe acute or recurrent leprosy type 2 reaction to evaluate the safety and efficacy of two doses of dovramilast, 100 mg and 150 mg. This Phase 2 trial aims to understand how well these doses improve skin lesions and assess any adverse effects. Participants will be randomly assigned to receive either 100 mg or 150 mg of dovramilast or standard care, which includes prednisolone or thalidomide in US sites only. The treatment period lasts 12 weeks, during which the responses to these interventions are monitored. The study is open-label, meaning both researchers and participants know which treatment is given. The trial includes a dose-ranging design to evaluate different strengths of dovramilast. During the 12-week trial, participants will undergo assessments including skin lesion evaluations, fever resolution, and neuropathy changes. Researchers will use the ENLIST severity scale and monitor the need for rescue medications. Safety is closely monitored by tracking adverse events. Additional follow-up up to 48 weeks will assess recurrences and drug exposure. Participants will be regularly evaluated with laboratory tests and photographic assessments to measure outcomes and ensure adherence.

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

Researchers are evaluating the safety and potential benefits of a single injection of allogeneic umbilical cord-derived mesenchymal stem cells UC-MSCs in adults aged 40 to 65 years with diabetic nephropathy, a kidney disease caused by diabetes. This study aims to find out if UC-MSC therapy is safe and well-tolerated when given directly into the kidneys and whether it can improve kidney function and reduce inflammation over a 12-month period. The trial is an open-label, single-arm study designed to explore these effects in patients who have chronic kidney disease stages III or IV related to diabetes. Participants will receive one intra-renal injection of UC-MSCs at a dose of 1 x 106 cells per kilogram of body weight. After the injection, they will be monitored over 12 months with scheduled visits at 1, 3, 6, 9, and 12 months to assess kidney function and inflammation. The treatment is given under imaging guidance to ensure accurate delivery. This trial does not include a comparison group and focuses on changes from baseline measurements following the intervention. During the study, participants will undergo evaluations of kidney function through estimated glomerular filtration rate eGFR, serum creatinine levels, and urine albumin-to-creatinine ratio. Inflammatory markers such as TNF-alpha and IL-10 will also be measured. Safety will be closely monitored by tracking any adverse events throughout the 12-month follow-up. The studys main outcome is to record the incidence of adverse events, with secondary outcomes focusing on changes in kidney function and inflammation markers over time.

This research aims to evaluate the effect of combining dlbs 3233 therapy with clomifen citrate compared to clomifen citrate alone on insulin resistance measured by HOMA-IR, follicle maturation, and menstrual cycle control in women diagnosed with Polycystic Ovary Syndrome PCOS. The study focuses on understanding how this combination therapy influences hormone levels and menstrual regulation, particularly in patients at Muhammadiyah Asri Medical Center Hospital. Participants will be randomly assigned to receive either the combination of dlbs 3233 and clomifen citrate or clomifen citrate alone. The study uses a quadruple masking design to compare the effectiveness of these treatments over a three-month period. The treatment effects will be monitored by measuring hormone levels such as serum AMH and evaluating follicle counts and sizes through ultrasound imaging. During the study, participants will have baseline assessments on the third day of their menstrual cycle, with follow-up evaluations at three months. These assessments include blood tests for HOMA-IR and AMH, as well as ultrasound examinations on day 12 of the menstrual cycle to monitor follicle development. Researchers will also track menstrual cycle regularity throughout the treatment period to measure the outcomes and safety of the therapies.